• Endoscopic Therapy
    • Risk Of Recurrence Of...
    • Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Endoscopic therapy,Recurrence crim,Hgd eac,Recurrence barrett esophagus,Barrett esophagus,Incidence recurrence,Complete remission,Recurrence barrett.

      Key People For Endoscopic Therapy

      Top KOLs in the world
      Christian Ell
      endoscopic resection photodynamic therapy small bowel
      Joseph Jao Yiu Joseph
      gastric cancer hong kong helicobacter pylori
      Jacques M Devière
      chronic pancreatitis pancreatic duct endoscopic treatment
      Nib Soehendra
      endoscopic ultrasound chronic pancreatitis esophageal varices
      Peter B Cotton
      chronic pancreatitis oddi dysfunction pancreas divisum
      Ernst Johan Kuipers
      helicobacter pylori colorectal cancer atrophic gastritis

      Risk of recurrence of Barrett’s esophagus after successful endoscopic therapy


      BACKGROUND AND AIMS: Previous estimates of incidence of intestinal metaplasia (IM) recurrence after achieving complete remission of IM (CRIM) through endoscopic therapy of Barrett's esophagus (BE) have varied widely. We performed a systematic review and meta-analysis of studies to estimate an accurate recurrence risk after CRIM.

      METHODS: We performed a systematic search of multiple literature databases through June 2015 to identify studies reporting long-term follow-up after achieving CRIM through endoscopic therapy. Pooled incidence rate (IR) of recurrent IM, dysplastic BE, and high-grade dysplasia (HGD)/esophageal adenocarcinoma (EAC) per person-year of follow-up after CRIM was estimated. Factors associated with recurrence were also assessed.

      RESULTS: We identified 41 studies that reported 795 cases of recurrence in 4443 patients over 10,427 patient-years of follow-up. This included 21 radiofrequency ablation studies that reported 603 cases of IM recurrence in 3186 patients over 5741 patient-years of follow-up. Pooled IRs of recurrent IM, dysplastic BE, and HGD/EAC after radiofrequency ablation were 9.5% (95% CI, 6.7-12.3), 2.0% (95% CI, 1.3-2.7), and 1.2% (95% CI, .8-1.6) per patient-year, respectively. When all endoscopic modalities were included, pooled IRs of recurrent IM, dysplastic BE, and HGD/EAC were 7.1% (95% CI, 5.6-8.6), 1.3% (95% CI, .8-1.7), and .8% (95% CI, .5-1.1) per patient-year, respectively. Substantial heterogeneity was noted. Increasing age and BE length were predictive of recurrence; 97% of recurrences were treated endoscopically.

      CONCLUSIONS: The incidence of recurrence after achieving CRIM through endoscopic therapy was substantial. A small minority of recurrences were dysplastic BE and HGD/EAC. Hence, continued surveillance after CRIM is imperative. Additional studies with long-term follow-up are needed.

      Sign-in to see all concepts, it's free!


    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.